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Abstract
Background: Microarray Comparative Genomic Hybridization (array CGH) provides a means to examine DNA
copy number aberrations. Various platforms, brands and underlying technologies are available, facing the user with
many choices regarding platform sensitivity and number, localization, and density distribution of probes.
Results: We evaluate three different platforms presenting different nature and arrangement of the probes: The
Agilent Human Genome CGH Microarray 44 k, the ROMA/NimbleGen Representational Oligonucleotide
Microarray 82 k, and the Illumina Human-1 Genotyping 109 k BeadChip, with Agilent being gene oriented, ROMA/
NimbleGen being genome oriented, and Illumina being genotyping oriented. We investigated copy number
changes in 20 human breast tumor samples representing different gene expression subclasses, using a suite of
graphical and statistical methods designed to work across platforms. Despite substantial differences in the
composition and spatial distribution of probes, the comparison revealed high overall concordance. Notably
however, some short amplifications and deletions of potential biological importance were not detected by all
platforms. Both correlation and cluster analysis indicate a somewhat higher similarity between ROMA/NimbleGen
and Illumina than between Agilent and the other two platforms. The programs developed for the analysis are
available from http://www.ifi.uio.no/bioinf/Projects/.
Conclusion: We conclude that platforms based on different technology principles reveal similar aberration
patterns, although we observed some unique amplification or deletion peaks at various locations, only detected
by one of the platforms. The correct platform choice for a particular study is dependent on whether the appointed
research intention is gene, genome, or genotype oriented.
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Microarray technology has become a powerful tool for
many scientific and diagnostic applications. In cancer
research the detection of genomic aberrations is crucial for
associating copy number changes with cancer phenotypes
or critical genes. For array Comparative Genomic Hybrid-
ization (array CGH), several methods and platforms have
been developed (see reviews [1,2]). Microarray copy
number detection systems differ in their probe origin
(BAC, cDNA or oligonucleotides [3-6]), production (spot-
ting, polymerization or microbeads), gene density (cover-
age of probes per gene or physical intercept),
hybridization (digestion, hybridization to reference), and
labeling technique (single or two-color systems). Labora-
tories are often required to evaluate the diverse microarray
formats, considering different biological questions, exper-
imental designs, material restrictions, and resolutions or
data processing challenges. Comparability and reproduci-
bility of results have always been important issues. Hence,
it is important to evaluate microarray platforms not only
based on their production characteristics but also using a
variety of analytical and statistical methods. A compara-
tive analysis of expression platforms has previously been
performed for gene expression measurements [7-10].
However, to our knowledge this is one of the first publica-
tions validating different array CGH formats using tumors
as material.
In this report, we compare three major DNA microarray
platforms: The Agilent Human Genome CGH Microarray
44 k, the ROMA/NimbleGen Representational Oligonu-
cleotide Microarray 82 k, and the Illumina Human-1 Gen-
otyping 109 k BeadChip. Oligonucleotide probes used for
the Agilent array cover both coding and non-coding
sequences, and most reporters are located in genes (gene
oriented arrangement). Oligonucleotides in the ROMA/
NimbleGen technology are based on Bgl II cutting sites,
hence reporters are more or less randomly distributed
across the entire genome providing a detailed picture of
the structure and organization of the complete genome
(genome orientated arrangement). The Illumina platform
on the other hand provides a dense, exon-centric view of
the genome (genotyping arrangement). The three plat-
forms were tested with a set of 20 primary breast tumor
samples. The samples are part of a larger cohort of stage I
and II primary tumors [11], including several distinct
expression subtypes expected to present with a number of
common aberrations for human breast cancer [12].
Results achieved were validated using different graphical
and statistical methods, many performed with the CGH-
Explorer analysis tool [13]. One goal of our study was to
investigate to what extent platforms of different nature
and design perform differently in terms of detecting aber-
rant structures, regarding both size and amplitude of copy
number changes. The results of the analysis were evalu-
ated to investigate whether the number of probes, density
distribution, probe localization, sensitivity and aberration
calling method had any effect on the overall performance
of the platform. Overall, we found that all platforms
included in this study give a similar general picture of the
DNA rearrangements in the tumors, including genomic
instability profiles, although some details differ substan-
tially.
Results
Whole genome analysis reveals overall similarity between 
platforms
The overall pattern is similar for all three platforms, as
confirmed by the results displayed in Figure 1. Here, the
overall frequency of amplification and deletion events in
the tumor samples was estimated for the three platforms
using the PCF (Piecewise Constant Fit) algorithm (see
Methods). Analysis of copy number changes using a
method based on a different principle (ACE – Analysis of
Copy Number Errors [13]) showed the same overall pat-
tern (see Additional file 1). All platforms detect the same
previously described common aberrations [14-16], like
high frequency of amplification of chromosomal regions
1q, 8q, 17q and deletions at 16q and 17p (Figure 1 and
see Additional file 1). Figure 2 illustrates that the plat-
forms reveal similar results with respect to amplification
peaks, though with some minor differences in amplitude
height and/or number of events, amplification region size
or pattern.
Figure 3 shows histograms for the distributions of the
PCF-fitted copy numbers and scatterplots comparing all
three platforms. There is strong correlation between plat-
forms, though with a notable difference in scale between
Agilent and the two other platforms, in accordance with
what other authors have reported on cell lines [17]. Com-
puting correlation coefficients between the platforms for
the tumor samples confirms this picture, with median
Pearson correlation of 0.77 for Illumina versus ROMA/
NimbleGen and close to 0.6 for Agilent versus the other
two platforms (see Additional file 2). We also applied
Total Least Squares (TLS) regression to fit regression lines
with zero intercept to the data in Figure 3. This analysis
yielded a median slope of 0.47 (IQR = 0.45) for Agilent
versus ROMA/NimbleGen, 0.55 (IQR = 0.26) for Agilent
versus Illumina, and 0.99 (IQR = 0.52) for ROMA/Nim-
bleGen versus Illumina. In Figure 4 the PCF estimated log
ratios are used to cluster the 60 cases obtained from the 3
platforms used on the 20 tumor samples. For 14 of the 20
tumors, the three platforms are clustered together at the
lowest possible cluster level and for 4 of the remaining
tumors Illumina and ROMA/NimbleGen cluster together.
Figure 5 shows ROC curves comparing the platforms pair-
wise with respect to aberration calling. Not surprisingly,Page 2 of 16
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BMC Genomics 2008, 9:379 http://www.biomedcentral.com/1471-2164/9/379the curves reveal an increasing correspondence as the
threshold for calling an aberration is increasing. This is
confirmed by inspecting the Area Under Curves (AUCs)
for the ROC analysis (see Additional file 3). A somewhat
better correspondence for Illumina versus ROMA/Nim-
bleGen than for Agilent versus the other platforms is seen.
Additional file 4 shows the degree of concordance
between the platforms with respect to the classification of
probes as amplifications, deletions or normal. The table is
based on one particular selection of detection thresholds,
the relative size of the thresholds reflecting the relative
scale of the log ratios of the different platforms. In all plat-
forms, the majority of probes are classified as being nor-
mal (i.e. neither amplified nor deleted). Probes that are
called as amplified (or deleted) on one platform are most
often called likewise or as normal on the platform consid-
ered for comparison. Opposite decisions, in the sense that
one platform calls an event as amplification and the other
platform calls a deletion, are very rare. Hence, in terms of
the direction of aberrations, the platforms are in large
agreement with each other. Nevertheless, there is a sub-
stantial proportion of probes that are called on one plat-
form and not on another. Note that the detection
Frequency plot of copy number aberrationsigur  1
Frequency plot of copy number aberrations. Copy number changes of 20 breast tumors are illustrated using the Piece-
wise Constant Fit (PCF) method in the CGH-Explorer program. Amplified regions are marked red and deleted regions are 
marked green. The proportion of calls (all samples combined, and deletions and amplifications combined) was adjusted to 12% 
(for details see Methods). For every platform, specific high frequency (over 50%) small amplification or deletion peaks are visi-
ble (marked by stars *). For the Agilent platform: amplifications at 3p, and 20q, deletions at 4p, twice at 5q, and 9q; for the 
ROMA/NimbleGen platform: amplifications at 15q and deletions at 14q; the Illumina platform shows lower frequency peaks, 
but picked up a unique amplification at 14q not seen by the other platforms. (Indicated with blue bars are regions, for which 
additional information is provided in Figure 7 and in Additional files 8, 11, and 12. Further are indicated with brown bars 
regions, for which additional information is in Additional files 9 and 10).Page 3 of 16
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number of concordant classifications of probes.
Instability indices, scoring the presence of localized
regions of clustered, narrow amplification peaks on a
chromosome arm, were determined (see Methods) for
each platform in each of the 20 tumor samples. In all plat-
forms, very high instability indices for chromosome 10 to
18 were found for patient 085 (green) on chromosome 11
and 12, and for patient 053 (red) on chromosome 17
(Figure 6). Additionally, high instability indices were
detected for patient 053 on chromosome 11, on chromo-
some 15 for patient 148 and on chromosome 14 for
patient 263.
Differences between the various platforms due to gene 
density or other factors
Despite the general consistency of the platforms, specific
variations in frequency and/or in aberration length are
visible (see PCF analysis in Figure 1 and the detailed plot
for chromosome 8 in see Additional file 5). Most of these
differences are due to variance in probe location or den-
sity. Probe location is depending on design (evenly dis-
tributed probes or clusters of several probes per gene),
which may be based on an automatic or manual strategy.
Reporters are not evenly spaced in any of the platforms,
accounting for differences in genome structure and natu-
ral variance in gene density. The distribution of probes for
the three different platforms is illustrated for the complete
genome (see Additional file 6) and in a close-up for chro-
mosome 8 (see Additional file 7). Of all platforms,
ROMA/NimbleGen comes closest to a uniform probe dis-
Piecewise constant regression for chromosome 6Figure 2
Piecewise constant regression for chromosome 6. Detection of genomic aberrations using the PCF method for all plat-
forms, shown for chromosome 6 for patient sample 146. Despite the great similarities in the overall size, structure and ampli-
tude of aberrations, several minor variations are seen.Page 4 of 16
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Scatterplot matrix comparing platformsFigure 3
Scatterplot matrix comparing platforms. Scatterplot matrices for 20 human breast cancer samples are shown for each 
pair of platforms. The scatterplot matrices are based on the vectors of PCF values. Panels off the diagonal: For each of the 20 
samples, PCF values are found for one platform were plotted against values found for another. Abscissa values are for the Agi-
lent 44 k (left column), ROMA/NimbleGen 82 k (middle column) and Illumina 109 k (right column) platforms. Ordinate values 
are for the Agilent 44 k (top row), ROMA/NimbleGen 82 k (middle row) and Illumina 109 k (bottom row) platforms. Panels on 
the diagonal: The distribution of the PCF filtered log ratios for all 20 breast cancer samples combined, for the Agilent 44 k (top 
left panel), ROMA/NimbleGen 82 k (middle panel) and Illumina 109 k (lower right panel) platforms, respectively.
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Clustering of 60 arrays representing 20 tumors on 3 platformsFigure 4
Clustering of 60 arrays representing 20 tumors on 3 platforms. The figure shows the result of clustering the PCF esti-
mated log ratios of 3 × 20 arrays obtained from the 3 platforms used on the 20 tumor samples (for PCF vector calculation see 
Methods). The samples were clustered using Spearman correlation and average linkage (A = Agilent 44 k, R = ROMA/Nimble-
Gen 82 k, or I = Illumina 109 k). For 14 of the 20 tumors, the three platforms are clustered together at the lowest possible 
cluster level, for 4 of the remaining tumors, Illumina and ROMA/NimbleGen are clustered together.
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number of reporters, particular for areas in 1q, 3p, 6p, 11q
centromeric, 12q centromeric, 16, 17 and 19. The Illu-
mina platform shows high-density islands of reporters at
6p, 11p telomeric, 12q centromeric, 17p telomeric,19p,
and 19q (see Additional file 6).
Interestingly, platform specific small high frequency
amplification or deletion peaks were found, as indicated
by (*) in Figure 1. Many were nearby the centromeric or
telomeric regions. The Agilent platform shows unique
small high frequency aberrations of amplification at 3p
and of deletions at 4p, twice at 5q, and 9q, and a larger
amplification increase towards the telomere of 20q.
ROMA/NimbleGen exhibits unique small high frequency
deletion at 14q and an amplification at 15q. Increasing
the aberration detection sensitivity, some extra platform
dependent unique small high frequency amplifications or
deletions are observed, e.g. at 14q for the Illumina plat-
form.
ROC curves for aberration callingFigure 5
ROC curves for aberration calling. ROC curves for the classification of 2936 uniformly spaced genomic loci into three cat-
egories (a) deletion, (b) normal and (c) amplified. Using a fixed threshold T across the genome, every locus was called as a dele-
tion if the PCF value was less than -T and as an amplification if the PCF value was larger than T. For every panel in the figure, 
one of the platforms is chosen as the correct classification (Agilent in row 1, ROMA/NimbleGen in row 2, and Illumina in row 
3). The ROC curves show the ability of each of the remaining two platforms to mimic this correct classification. There are four 
curves in each panel, corresponding to the thresholds T = 0.25, 0.50, 0.75, 1.00 (shown in blue, green, red and cyan, respec-
tively) used to define the correct classification. The points on a ROC curve correspond to different choices of T for the other 
platform under consideration.
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Instability index for chromosome 10 to 18Figure 6
Instability index for chromosome 10 to 18. The instability index, indicating regions of clustered, narrow peaks of chro-
mosomal rearrangements located at a chromosome arm or entire chromosome, was calculated for all samples for all chromo-
somes. Sample 085 shows highest instability index for chromosome 11 and 12 for all platforms, followed by sample 053 in 
chromosome 11. For chromosome 14 sample 263 has the highest instability index, for chromosome 15 sample 148. Small dif-
ferences are seen for chromosome 17, here, the Agilent and ROMA/NimbleGen platforms indicate that sample 053 has the 
highest index, however, using the Illumina platform, sample 148 has the highest value. (Samples with high instability index (>2) 
are colored: Sample 053 = red, sample 085 = green, sample 148 = violet, and sample 236 = blue).
Agilent 44k
ROMA/NimbleGen 82k
Illumina 109k
BMC Genomics 2008, 9:379 http://www.biomedcentral.com/1471-2164/9/379We suspect some of the observed unique differences in
copy number aberration calling to be of biological impor-
tance. We therefore examined examples of these features
(Figure 1, indicated by blue or brown bars over chromo-
somes 3, 14, 15, and 20) in more detail (in close-ups in
Figure 7 and by providing detailed information see Addi-
tional files 8, 9, 10, 11, 12): At chromosome 3, between
position 50.36–50.64 Mb in over 75% of all samples the
Agilent platform identifies a region with small amplifica-
tions (Figure 7a, for exact probe localization see Addi-
tional file 8). Two strongly amplified reporters covering
the genes CACNA2D2 (H.s. calcium channel, alpha 2/
delta subunit 2) and CISH (H.s. cytokine inducible SH2-
containing protein) cause the amplification detection in
the Agilent platform. The Agilent platform further detects
a larger unique region with amplifications for telomeric
region 20q, between 60.00–60.50 Mb (Figure 7b). Genes
in this region (see Additional file 12) include SS18L1 (H.s.
synovial sarcoma translocation gene on chromosome 18-
like), OSBPL2 (H.s. oxysterol binding protein-like 2) and
LAMAY5 (H.s. laminin, alpha 5), a gene of potential
importance as it is found in the intrinsic gene list used for
the classification of breast cancer subtypes [18]. Further, a
unique short deletion is detected in over 50% of all sam-
ples using the ROMA/NimbleGen platform for the centro-
meric region of chromosome 14, at 19.00–20.00 Mb (see
Additional file 9), covering a region of genes including
CCNB1IP1 (H.s. cyclin B1 interacting protein 1), APEX1
(H. s. nuclease multifunctional DNA repair enzyme 1)
and TEP1 (H. s. telomerase-associated protein 1). Interest-
ingly, an adjacent unique region detected solely by the
Illumina platform in chromosome 14 stretches from
21.20–22.00 Mb (see Additional file 10). Unique small
amplification peaks exclusively detected by one of the
platforms are likely to be due to differences in reporter
density, as seen for the ROMA/NimbleGen platform at
chromosome 15, between 18.40–20.40 Mb (Figure 7c).
This centromeric peak is densely covered by 19 ROMA/
NimbleGen reporters: However, the Agilent platform has
a single reporter and Illumina platform provides only 2
reporters for this area (see Additional file 11).
Discussion
Microarray-based comparative genomic hybridization
allows the construction of high-resolution maps of
genome-wide copy number alterations. Array CGH ena-
bles localization of genomic aberrations in tumors, iden-
tification of critical genes, and classification of
chromosomal changes [1], indicating susceptibility or
activation of tumor initiation and progression [19]. Dif-
ferent arrays have been used for CGH-studies starting with
cDNA-, followed by BAC-, and more recently by high den-
sity oligonucleotide-arrays [3-5,20,21]. Only few compar-
isons of the various array CGH platforms have been
performed and those we are aware of [17,22,23] were
based on other platforms and/or cell lines rather than on
tumor data. For example, in [17] the focus is primarily on
reproducibility, signal-to-noise ratio and resolution dif-
ferences.
We compared the Agilent Human Genome CGH 44 k oli-
gonucleotide Microarray, the Representational Oligonu-
cleotide Microarray ROMA/NimbleGen 82 k array, and
the Illumina SNP-CGH Human-1 (109 k) BeadChip array
platforms using human breast tumor samples. Whole
genome analysis of called copy number alterations reveals
a great overall similarity and strong correlation between
platforms. However, in concordance with [17] we
detected a notable difference in the scale of the log ratios
between Agilent and the two other platforms. In their cell
line study with known relative copy number, [17] found
markedly higher signals for the Agilent 44 k than for the
high-resolution ROMA/NimbleGen 1500 k. Numerically,
the factors detected in their study correspond well to the
factor of about 0.5 found in our TLS analysis of our tumor
samples. Agilent 44 k CGH arrays have a gene oriented
arrangement being enriched particularly for cancer rele-
vant genes with local high variation of number of report-
ers. The combination of these two features may be the
reason for the high number of specific small high fre-
quency amplification or deletion peaks particular in the
Agilent platform (Figure 1 and see Additional file 6). The
ROMA technology, invented at Cold Spring Harbor Labo-
ratory and by NimbleGen [20], is based on representative
oligonucleotide probes designed for fragments of the
human genome sequence, which are more or less ran-
domly distributed across the genome. The ROMA/Nim-
bleGen arrays provide a gene-independent arrangement
of the structure of the complete genome at a high resolu-
tion. The bead-based Human-1 109 k arrays from Illu-
mina provide an exon-centric view of the genome through
their 109 k SNP markers, of which 70% are located in
gene exons or within 10 kb of transcripts. This platform
employs an allele-specific primer extension assay using
two probes (bead types) in one color channel to score Sin-
gle-Nucleotide Polymorphisms (SNPs) [24,25].
It is important to be able to distinguish between real copy
number variation and variation related to the technical
processing and analysis of the arrays. Various programs,
web-based tools and statistical software packages are
available for exploring and analyzing array CGH data, e.g.
[13,26,27], with different accuracy for the estimation of
aberrations callings [26]. A major advantage of the aberra-
tion calling method used here (PCF), as compared to
many other aberration calling algorithms, is that its math-
ematical form makes it easy to adjust parameters to adapt
to the specific platforms to obtain an appropriate compar-
ison.Page 9 of 16
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BMC Genomics 2008, 9:379 http://www.biomedcentral.com/1471-2164/9/379In comparing platforms, one should be aware that higher
density of probes not necessarily implies an improved
effective resolution. The effective resolution of a platform,
defined as the smallest genomic range for which a reliable
classification can be made with respect to aberration sta-
tus (deleted, normal or amplified), clearly depends on the
platform's probe density and on the platform's SNR (Sig-
nal-to-Noise Ratio). Let D denote the absolute change in
Platform differences in narrow frequent amplification peaksFigure 7
Platform differences in narrow frequent amplification peaks. a.) The Agilent platform identifies a small amplification 
peak at chromosome 3, between 50.36–50.64 Mb (for exact probe localization, aberration calling, reporter coverage and gene 
identification see Additional file 8). The area is called as amplified using the Agilent platform due to two strongly amplified 
reporters covering the genes CACNA2D2 (H.s. calcium channel, alpha 2/delta subunit 2) and CISH (H.s. cytokine inducible 
SH2-containing protein). b.) A larger unique amplification region is detected by the Agilent platform at chromosome 20q, 
between 60.00–60.50 Mb. Reporters covering SS18L4, OSBPL2, and LAMA5 are highly amplified, causing this region to be 
called as amplification in the Agilent platform. Reporters in the other platforms either miss these genes or are located nearby 
at different positions (for exact probe localization, aberration calling, reporter coverage, and gene identification see Additional 
file 12). c.) The ROMA/NimbleGen platform detects a unique small amplification peak at chromosome 15, between 18.40–
20.40 Mb (for details of exact probe localization, aberration calling, reporter coverage and gene identification see Additional file 
11), while the Agilent platform has one single reporter and Illumina platform provides only 2 reporters in this specific area, and 
are therefore unable to detect amplifications in this region.
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BMC Genomics 2008, 9:379 http://www.biomedcentral.com/1471-2164/9/379true intensity log-ratio corresponding to the smallest copy
number alteration that we want to be able to detect, and
suppose the observed intensity log-ratios are normally
distributed around the true log-ratio with standard devia-
tion SD. Then, we may define SNR = D/SD. To be able to
detect the smallest alteration while controlling the Type I
and Type II error rates, the number of probes in the region
must exceed a number that scales as the inverse square of
SNR. Thus, the effect of doubling the signal-to-noise ratio
is comparable to that of increasing the probe density by a
factor of four. Of course, an added effect of increasing the
probe density, as opposed to improving the SNR, is that
local aberration details may be revealed that are partly or
completely absent in lower resolution scans.
The content and performance characteristics of a particu-
lar platform influence its applicability for a certain study
type. We conclude that for gene detection and gene-ori-
ented research the Agilent or the Illumina platform are to
be preferred. On the other hand, the ROMA/NimbleGen
approach, showing a compact picture of the entire
genome structure, is the method of choice for exploration
of the various mechanisms leading to different types of
genomic instability such as Chromosomal Instability
(CIN) or Microsatellite Instability (MIN). The Illumina
SNP-CGH arrays can be utilized for detecting LOH and
allelic ratios in detecting aberrations. We are aware that
several newer platforms with increased reporter numbers
exist. However, the aim of this study was to assess to what
extent platforms of different nature and design can result
in differences in detection of some copy number aberra-
tion patterns.
In general, when comparing samples hybridized to differ-
ent platforms the following steps should to be taken, sup-
posing the data have been normalized according to the
platform used: Fit a regression model suitable for copy
number data, such as PCF, to obtain estimated log ratios
for a desired set of genomic loci. Parameters (for PCF: The
penalty parameter and the lower limit on the size of a pla-
teau) should reflect the probe density and noise level. If
some samples have been hybridized to both (all) plat-
forms, frequency plots (like Figure 1) should be used to
estimate the difference in scale. Then perform aberration
calling on the basis of the above fit, compensating for
scale differences when estimates are available. Finally,
caution should be taken when comparing the small-scale
structure of aberrations, since our analysis indicates that
the similarities found by different platforms in the higher-
level structure are not necessarily accompanied by corre-
spondence in the detailed structure.
Conclusion
Using 20 breast tumor samples and adjusted analytical
methods, we observed high overall concordance between
the three platforms evaluated, despite substantial differ-
ences in the platform composition. Both correlation and
cluster analysis indicate a somewhat higher similarity in
results obtained by ROMA/NimbleGen and Illumina than
between Agilent and the other two platforms. Some short
amplifications or deletions of potential biological impor-
tance were revealed by only one of the platforms. Detailed
examination of these sites indicated that the discrepancy
was mainly due to the density and spatial distribution of
probes, and other platform specific features. Further stud-
ies are needed to verify on the potential biological impor-
tance of the sites. The correct platform for a particular
study is dependent on the research intention, whether it is
gene, genome, or genotype oriented, and on region or
location of interest. A complete genomic tiling array
including high density gene oriented reporters may be the
ultimate goal for the study of genomic alterations in can-
cer.
Methods
Patient samples
From May 1995 to December 1998, 920 patients referred
for surgical treatment of breast cancer were included from
five different hospitals in the Oslo region in a large study
on detection of isolated tumor cells in bone marrow [28].
From theses 920 patients, tissue samples from 20 breast
carcinomas were selected for this study. All 20 breast car-
cinomas contained >40% tumor cells, the majority of the
tumor specimens represent tumor size T1/T2, node status
N0/N1 (9/11) and histological grade 2 or 3. The 20 sam-
ples have been classified into five clinically relevant tumor
subclasses [18]. Tumor DNA was extracted using an ABI
341 Nucleic Acid Purification System (Applied Biosys-
tems) according to the manufacturer's protocol.
Agilent platform
Agilent's Human Genome CGH Microarray 44 k contains
44,255 in situ synthesized 60-mer probes (3,877 con-
trols) designed for studying copy number changes and
representing most of the known or predicted human
genes. The probes are, after manufacturers description,
enriched for cancer relevant genes representing both cod-
ing and non-coding sequences on the chromosomes [29].
Experiments using Agilent arrays were performed at the
Department of Genetics at The Norwegian Radium Hospi-
tal, Oslo, Norway using female human genomic DNA
(Promega) as reference and following the Agilent recom-
mended standard protocol (see Additional file 13). The
arrays were scanned using an Agilent scanner, data extrac-
tion, filtering and normalization were conducted using
the Feature Extraction software version A.7.5.1 (Agilent
Technologies). The CGHAnalytics program version 3.4.40
(Agilent technologies) was used to export the array CGH
data for usage in other analytic programs.Page 11 of 16
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The Representational Oligonucleotide Microarray Analy-
sis (ROMA) has been developed at Cold Spring Harbor
Laboratory [20]. The procedure is based on representative
oligonucleotide probes designed by analyzing Bgl II
restriction fragments of the human genome sequence.
Approximately 85,000 70-mer probes are randomly com-
bined on a single chip, providing a more or less even dis-
tribution across the human genome. ROMA experiments
were prepared and analyzed at the Cold Spring Harbor
Laboratory, New York, USA using male reference DNA
(CHP-SKN-1 = 46, XY male) and following the standard
ROMA/NimbleGen protocol (see Additional file 13).
Arrays were immediately scanned using an Axon GenePix
4000b scanner (pixel size as set to 5 μm). The GenePix Pro
4.0 software was used for identification and quantifica-
tion of probe intensities. Measured intensities without
background subtraction were used to calculate ratios.
ROMA/NimbleGen data were normalized using an inten-
sity-based lowness curve fitting algorithm [30].
Illumina platform
The SNP-CGH experiments were performed using the
Infinium™ I assay on the Human-1 Genotyping BeadChip
representing 109,365 loci (~109 k) [21,24]. Each allele is
represented by two unique beads, having an average of
30-fold redundancy per unique bead. The BeadChips are
constructed by attaching 50-mer probes to 3 μm-diameter
beads, which are randomly assembled onto the chips con-
taining ~3 μm diameter wells. In addition to the 50-mer
probe sequence, a ~30-mer address sequence is present on
each bead to allow identification of each bead by decod-
ing [24]http://www.illumina.com/home.ilmn. The Illu-
mina experiments were prepared and analyzed at Uppsala
University, Uppsala, Sweden. For the Illumina Human-1
BeadChip (109,365 loci) samples were prepared and
processed according to the manufacturer's protocol (see
Additional file 13). Signal detection was conducted using
the Illumina BeadArray Reader (Infinium I FastScan scan-
ner protocol) while identification of bead positions and
raw-data extraction were performed using the BeadScan
software. Following data acquisition, data from patient
blood samples (of 112 corresponding blood-tumor pairs)
were subjected to clustering using the algorithm supplied
in the BeadStudio application. These clusters were further-
more applied to the tumor arrays, and manual review of
peripheral GenCall (GC) and Cluster Separation (CS)
scores was performed. After clustering and QC-review, we
extracted the log R-ratios for the tumor data. This ratio
results from dividing the normalized R-value (observed)
by the expected normalized R-value [21].
Statistical methods and analytical tools
The PCF algorithm
The PCF algorithm is an extension of the Potts filter
method described by Winkler et al. [31] and seeks the best
possible fit to the data using one or more constant pla-
teaus. Let  = {(xi, yi), i = 1,..., n} be copy number data
for one chromosome in one individual, where a = x1 ≤ x2
≤  ≤ xn = b are the locations of the probes along the chro-
mosome and y1,..., yn are the corresponding log-trans-
formed copy number ratios. Then the PCF filtering
algorithm computes the solution  to the
penalized optimization problem
the first term in braces being the goodness of fit and the
second term being a penalty proportional to the number
of discontinuities (jumps) in the function. The constant λ
> 0 controls the trade-off between the two terms. Observe
that the transformation (y, λ) → (σy, σ2λ) induces a cor-
responding transformation  of the solution. Let-
ting the penalty coefficient be λ = τσ2 where τ > 0 is a
constant and σ2 is the variance of the log ratios, the
number of discontinuities or their locations will not be
scale dependent. To compare different platforms we select
a platform-independent value of τ (say τ = 9) and for any
particular chromosome and array let λ = τ  where 
is the estimated variance of the log ratios. The PCF algo-
rithm used in this paper also allows the user to specify a
lower limit on the size (number of probes) of a plateau in
the piecewise constant function to be determined. To
compensate for the platform differences in average probe
density, the limit was set to 10 probes for Agilent, 18 for
ROMA/NimbleGen and 25 for Illumina.
Cross-platform copy number comparison
Several of the analyses in this paper involve the compari-
son of copy number measurements across platforms. As
the actual measurement probes for one platform differ in
number and genomic locations from that of another plat-
form, some assumptions must be made about the copy
number ratio between neighboring probes in order to
carry out a meaningful comparison. The PCF algorithm
provides a useful starting point, as it eliminates (or
reduces) through smoothing the random variability
owing to the measurement process, while at the same time
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ratios which is defined everywhere on the genomic range
of the data. Specifically, the PCF solution  may be
extended to a function defined on the whole range of the
data:
where ui = (xi + xi+1)/2. This means that solutions obtained
for different platforms (with different probe locations)
can be directly compared through interpolations of the
PCF curves in identical genomic loci chosen to be identi-
cal for all platforms. For the analyses in this paper, the loci
were chosen to be uniformly spaced across the whole
genomic, with a distance of 1 Mb between neighboring
loci (leading to a total of 2936 genomic loci in which the
PCF function value was determined by the above interpo-
lation formula). Thus, for every array a vector z of PCF
function values of length m = 2936 was found and was
used to produce scatterplots comparing different plat-
forms, to cluster the arrays, to compare aberrations across
platforms, etc.
Aberration calling
To call aberrations in a tumor, a two-step procedure is
applied to the log-transformed copy number ratios. First,
a piecewise constant regression function is fitted to the log
ratios, using the PCF algorithm described above. Next, a
gene is called if the fitted regression value for the gene is
above a certain positive threshold T (amplification call) or
below -T (deletion call). To validate the results obtained
from PCF, we also applied an unrelated aberration calling
algorithm called ACE [13] to the data. Overall, the aberra-
tion patterns found by the two methods are very similar.
ROC curves
To assess the degree of similarity between the aberration
patterns found with different platforms, we consider the
ability of each platform to mimic the other two platforms'
classification of genomic loci. For any platform and any
sample, we first apply the PCF algorithm to the log-trans-
formed copy number ratios to fit a piecewise constant
function. Let T be a fixed positive threshold. For 2936
genomic uniformly spaced genomic loci across the
genome, we classify the locus as a deletion, if the corre-
sponding PCF value is less than T, and as amplification if
the PCF value is larger than T. Otherwise, the genomic
locus is classified as normal. This is done for various
choices of T, for every one of the 20 samples and for every
platform. For any given pair of platforms, we consider the
classification based on one platform as the correct (true)
classification and calculate an ROC curve for the classifi-
cation based on the other platform relative to the first one.
The points on an ROC curve correspond to different
threshold values T for the classification based on the sec-
ond platform (T ranging from 0 to the maximal PCF value
for that platform). Different ROC curves may be produced
by varying the threshold used to define the correct classi-
fication.
Total least squares regression
To investigate possible differences in scale between the log
ratio measurements obtained for the different platforms,
we fitted for every pair of platforms regression lines with
no intercept to PCF interpolation values, obtained on a
regular genomic grid consisting of 2936 loci. Total Least
Squares regression was used for this purpose. While an
ordinary least squares regression fit takes into account
measurements errors in the dependent variable only, TLS
also accounts for measurement errors in the independent
variable. This leads to an improved estimate of the slope
for data in cases, where both platforms are subject to sub-
stantial measurement error. Estimates of slopes were
found separately for each array, and the median slope is
reported together with a robust measure of spread called
Interquartile Range (IQR), defined as the difference
between the 3rd and 1st quartile of the 20 slopes.
Detection of firestorms
Hicks et al. (2006) observed in some tumors what they
referred to as a firestorm in the array CGH profile. A fire-
storm is the presence of at least one localized region of
clustered, relatively narrow peaks of amplification, with
each cluster being confined to a single chromosome arm
[30]. In order to detect firestorms, we define a mathemat-
ical measure called a firestorm index, designed to quantify
the degree of instability in a chromosome. As before, let
 = {(xi, yi), i = 1,..., n} be the copy number observations
for one particular chromosome and let  be
the piecewise constant fit found by the PCF algorithm
described above. Suppose  is an estimate of the vari-
ance of the data around the true mean. Select the points xi
for which  and at least one of the values 
are outside the interval , and denote these points t1
< ... <td. Let a1 < ... <ad be the corresponding log ratios. For
a window w spanning s bases of the chromosome (this
paper uses s = 35 Mb), define
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BMC Genomics 2008, 9:379 http://www.biomedcentral.com/1471-2164/9/379where N(ω) is the number of turning points (i.e. local
minima and maxima) in the sequence {(x, ), xi ∈ ω}.
The firestorm index is defined as the maximum of γ(ω) as
ω ranges over all windows that cover s bases of the chro-
mosome.
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Additional file 1
Whole genome analysis of copy number errors by ACE. Illustrated are 
frequency plots for amplified (red) or deleted (green) regions for 20 breast 
cancer samples along the genome using copy number errors (ACE) anal-
ysis and graphical tools in the CGH-Explorer program [13]. ACE is less 
sensitive than PCF, but it detects well known amplification regions for 
chromosome 1, 8, and 17, in addition to an amplification increasing 
towards the telomere for chromosome 20, only detected in the Agilent plat-
form.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-379-S1.pdf]
zˆ i
Additional file 2
Platform correlation. The three boxplots give the correlations between the 
platforms. Correlations are based on PCF values found for every array and 
for a regular genomic grid (see the Methods section on cross-platform copy 
number comparison), and the box plots shows the distribution of the 20 
correlations found for every pair of platforms.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-379-S2.pdf]
Additional file 3
Genomic aberration on chromosome 8 using PCF method. Single plot 
graphical views for each of the 20 tumor samples are shown using the 
Piecewise Constant Fit (PCF) method in the CGH-Explorer program for 
detection of copy number changes. Amplifications are highlighted in red 
and deletions are marked with green with color intensity coding from -0.5 
to 0.5 and an overall high similarity are seen (see Methods). Despite wide 
similarities some differences are also detected. For example, sample 031 
shows an interrupted deletion at the p arm for the Agilent and Illumina 
platforms missing in the ROMA/NimbleGen platform, further sample 
042 shows a low copy number gain of several regions on 8q by the ROMA/
NimbleGen and Illumina platforms, missing in the Agilent platform.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-379-S3.pdf]
Additional file 4
Gene density plot for the whole genome. The distribution of probes along 
the complete genome is illustrated for the Agilent 44 k, ROMA/Nimble-
Gen 82 k, and Illumina 109 k platforms with platform-dependent band-
width selection (see Methods). Uneven distribution is seen for all 
platforms with areas of high density in certain chromosomes or chromo-
some arms.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-379-S4.pdf]
Additional file 5
Probe density plot for chromosome 8, The distribution of probes is illus-
trated for the complete genome for three different platforms with band-
width size, Agilent = 10-6, ROMA/NimbleGen = 10-6, and Illumina = 10-
5 for example chromosome 8 (gene density for the entire genome is pre-
sented in Additional file 6).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-379-S5.pdf]
Additional file 6
Area Under Curve for ROC analysis for the three platforms Agilent 44 k, 
ROMA/NimbleGen 82 k, and Illumina 109 k.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-379-S6.xls]Page 14 of 16
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